SMTL ID : 4cqe.2 (1 other biounit)

B-Raf Kinase V600E mutant in complex with a diarylthiazole B-Raf Inhibitor

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.30 Å

Oligo State

monomer

Ligands

1 x CQE: N-{4-[2-(1-cyclopropylpiperidin-4-yl)-4-(3-{[(2,5-difluorophenyl)sulfonyl]amino}-2-fluorophenyl)-1,3-thiazol-5-yl]pyridin-2-yl}acetamide(Non-covalent)

CQE.1: 20 residues within 4Å: Chain A: I.18, V.26, A.36, K.38, L.60, L.69, F.71, I.82, V.83, T.84, Q.85, W.86, C.87, G.89, N.135, F.138, I.147, G.148, D.149, F.150 14 PLIP interactions: 14 interactions with chain A Hydrophobic interactions: A:A.36, A:L.60, A:L.69, A:L.69, A:F.71, A:I.82, A:T.84, A:W.86, A:N.135 Hydrogen bonds: A:C.87, A:C.87, A:D.149, A:F.150 Halogen bonds: A:V.83

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Pulici, M. et al., Optimization of Diarylthiazole B-Raf Inhibitors: Identification of a Compound Endowed with High Oral Antitumor Activity, Mitigated Herg Inhibition, and Low Paradoxical Effect. Chemmedchem (2015)

Release Date

2014-12-10

Peptides

SLC45A3-BRAF FUSION PROTEIN: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
B

SLC45A3-BRAF FUSION PROTEIN

Related Entries With Identical Sequence